1 / 6

Global Sales of ADCs in 2022 – UP to 7 Billion

Currently, a total of 15 antibody-drug conjugates (ADCs) are currently approved for marketing globally. The global ADCs market size was valued at USD 5.31 billion in 2021. And in 2022, the total sales of these ADC drugs are nearly $7 billion.

sunnyfang1419
Download Presentation

Global Sales of ADCs in 2022 – UP to 7 Billion

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Biopharma PEG https://www.biochempeg.com Global Sales of ADCs in 2022 – UP to 7 Billion Currently, a total of 15 antibody-drug conjugates (ADCs) are currently approved for marketing globally. The global ADCs market size was valued at USD 5.31 billion in 2021. And in 2022, the total sales of these ADC drugs are nearly $7 billion. Figure. ADC Market size from 2016 to 2022 From the disclosed FY2022 financial statements, ADC drugs such as Seagen/Takeda's Adcetris, Roche's Kadcyla and Polivy, Gilead's Trodelvy, and Daiichi Sankyo/AstraZeneca's Enhertu, have been approved for new indications and accelerated to seize the market. Of particular interest is the explosive sales growth of Enhertu from Daiichi Sankyo/AstraZeneca, which surged from $426 million to $1.234 billion. 2021 Sales ($ million) Trade Names Target antigens Approved Date 2022 Company Sales ($ million)Year-over-year 2000/5/17; 2017/9/1 2011/8/19 2013/2/22 Mylotarg Pfizer CD33 / / Adcetris Kadcyla Seagen/Takeda Roche CD30 HER2 1306 2178 1480 2265 +12.8% +7%

  2. Biopharma PEG https://www.biochempeg.com Besponsa Lumoxiti Polivy Padcev Pfizer CD22 CD22 CD79B 2019/6/10 Nectin-4 2019/12/18 2017/6/28 2018/9/13 192 / 326 461 219 / 591 754 +14.1% AstraZeneca Roche Astellas/Seagen Daiichi Sankyo/AstraZeneca Gilead GSK Rakuten Medical ADC Therapeutics RemeGen Genmab/Seagen ImmunoGen +81.3% +63.6% Enhertu HER2 2019/12/20 426 1234 +189.7% Trodelvy Blenrep Akalux Zynlonta Aidixi Tivdak ELAHERE Trop-2 BCMA EGFR CD19 HER2 TF FRα 2020/4/22 2020/8/5 2020/9/25 2021/4/23 2021/6/8 2021/9/20 2022/11/14 380 122 / 30 10 6 / 680 / / / / / / +78.9% Table. ADCs Sales in 2022 Kadcyla: Top ADC Seller Kadcyla (Adptrastuzumab emtansine), co-developed by Roche and ImmunoGen, was first approved by the FDA on February 22, 2013 for HER2-positive metastatic breast cancer. Kadcyla reported revenues of CHF 2.08 billion, or approximately $2.265 billion, in the full year 2022, with year-over-year (CER) growth of 7%, showing slower growth compared to the 16% growth rate in 2021. In 2023, Roche announced a price cut of more than 50% for Kadcyla in China, hoping to capture the market through price cuts. Adcetris Sales in 2022 Adcetris® (brentuximab vedotin), originally developed by Seagen (formerly SeattleGenetics) and later co-developed with Takeda, is the first ADC approved for first-line treatment targeting CD30/CD16, and has gained worldwide popularity since its

  3. Biopharma PEG https://www.biochempeg.com launch. From 2011 to 2021, Adcetris has been approved by the US FDA, China NMPA and EU EMA for the treatment of Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). Adcetris has global sales of up to $659 million in 2020; doubling to $1.306 billion in 2021 and further growing to $1.48 billion (JPY 194.3 billion) in 2022. Enhertu Sales in 2022 Enhertu, co-developed by Daiichi Sankyo and AstraZeneca, has shown the fastest sales growth. In 2019, Enhertu first won FDA approval for some patients with HER2-positive unresectable or metastatic breast cancer. Two years later, the drug won an indication for previously treated HER2-positive advanced gastric cancer and non-small cell lung cancer (NSCLC). It is also the world's first therapy for HER-2 low-expressing breast cancer. Figure. Enthertu Indications Benefiting from the approval of new indications in 2022 and the gradual penetration into more markets, Enhertu broke the billion-dollar barrier this time with sales of JPY 161.6 billion (approximately $1.234 billion), an almost twofold increase compared to the previous year's sales of $426 million.

  4. Biopharma PEG https://www.biochempeg.com In addition, Enhertu is not just satisfied with its current results. In addition to breast, lung and gastric cancers, Enhertu is also conducting clinical trials for a wide range of cancers, including colorectal, uterine, pancreatic and biliary tract cancers. Trodelvy Sales in 2022 TRODELVY® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate. Currently, Trodelvy has been approved in more than 40 countries worldwide, with the first approval in 2020 by the FDA for the treatment of patients with metastatic triple-negative breast cancer (TNBC) who have failed two or more systemic therapies, as well as accelerated approval for the second-line treatment of patients with metastatic uroepithelial cancer. Trodelvy sales increased 78.9% to $680 million for the full year 2022 compared to 2021. Meanwhile, the drug has just been approved for the treatment of HR+/HER2- breast cancer and is expected to continue its explosive growth in 2023. Figure. Trodelvy sales 2022

  5. Biopharma PEG https://www.biochempeg.com Future Prospects of ADCs Currently, the enthusiasm for ADC drug development is high. As of June 2022, there are more than 400 ADC drugs in development worldwide, of which more than 200 are in the clinical stage. In terms of targets, except for ADCs targeting HER2 which are mostly laid out in breast cancer and gastric cancer, other products are developed in tumor indications with high expression of target proteins such as TROP2 and Claudin18.2, including solid tumors such as breast cancer, gastric cancer, bladder cancer, (non-)small cell lung cancer, ovarian cancer, pancreatic cancer, and hematologic tumors such as lymphoma and multiple myeloma. However, there is also a lot of concern in the market about the status of repeated development. Today, some of the target tracks are already more crowded, and the product launch will face more brutal competition The market is also prone to excessive competition from homogeneous R&D. Currently, the global market for ADCs currently boasts a size of nearly $7 billion. Yet, the market is still under cultivation as most of the approved ADC drugs are backline therapies and most of them have been approved for a relatively short period of time. According to the current market growth rate, it is inevitable that the market space will exceed USD 10 billion soon. How to avoid laying out popular indications with the help of cutting-edge technology to target differentiated targets and seize market opportunities in the future? This is the question for the companies participating in the ADC field. Biopharma PEG offers a variety of PEG linkers to facilitate antibody-drug conjugate (ADC) development projects. All PEG linkers are of >95% purity and they are the basic building blocks for a successful ADC.

  6. Biopharma PEG https://www.biochempeg.com Related Articles: ADC Drugs Global Sales of 2021 and Future Prospects Enhertu (Trastuzumab Deruxtecan): Magic ADC Drug HER2 Targeted Therapies In Breast Cancer The Rise of the TROP2-Directed ADCs for Solid Tumors Claudin18.2 Targeted Therapies In Cancer

More Related